BMY Q2 2024 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q2 2024 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$12.2B+8.7% YoY

Gross Profit

$6.8B55.7% margin

Operating Income

$2.6B21.2% margin

Net Income

$1.7B13.8% margin

EPS (Diluted)

$0.83

QoQ Revenue Growth

+2.8%

Cash Flow

Operating Cash Flow

$2.3B

Free Cash Flow

$2.1B

Stock-Based Comp.

$125M

Balance Sheet

Total Assets

$94.6B

Total Liabilities

$77.6B

Stockholders' Equity

$17.0B

Cash & Equivalents

$6.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12.2B	$11.2B	+8.7%
Gross Profit	$6.8B	$6.1B	+11.0%
Operating Income	$2.6B	$1.9B	+33.0%
Net Income	$1.7B	$2.1B	-19.0%

Revenue Segments

Eliquis

$3.4B28%

Opdivo

$2.4B20%

Revlimid

$1.4B11%

Pomalyst/Imnovid

$959M8%

Orencia

$948M8%

Yervoy

$630M5%

Reblozyl

$425M3%

Sprycel

$424M3%

Other Growth Brands

$341M3%

Opdualag

$235M2%

Abraxane

$231M2%

Other Legacy Brands

$222M2%

Breyanzi

$153M1%

Zeposia

$151M1%

Camzyos

$139M1%

Abecma

$95M1%

Sotyktu

$53M0%

Krazati

$32M0%

Geographic Segments

UNITED STATES

$8.8B72%

Rest Of World

$3.2B26%

Other Region

$176M1%